etherna, an mRNA/LNP technologies company, has announced that Bernard Sagaert has been confirmed as Chief Executive Officer. At the same time Marijn Dekkers, an existing Board Member representing investor Novalis LifeSciences LLC, has been appointed Chairman of the Board.
Sagaert’s appointment follows an interim 12-month period during which he has successfully led the company’s pivot to a new partnership-driven business strategy.
etherna works with ife science and pharma companies in the fast-growing nucleic acid sector, providing RNA-based chemistry, custom LNP delivery platforms, and GMP process knowhow.
Sagaert said: “etherna’s new partnership strategy has been very well-received in both Europe and the US. With the help of our highly dedicated and professional team, I now intend to continue and accelerate our drive towards becoming the premier discovery and development partner for pharma and biotech aiming to deliver novel RNA-based therapeutics to patients.”